Clinical trial · Observational
ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy
ICG vs Blue Patent as a Tracer in the Performance of TAD in Patients With cN1 Breast Carcinoma After Neoadjuvant Chemotherapy
NCT06339658CI-TRIAL-00088799recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 18, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260918-000001
Summary
Brief summary (as posted)
To validate the use of ICG as a tracer during TAD in patients with cN1 breast carcinoma after neoadjuvant chemotherapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Axillary Metastases | Breast Neoplasm | PROBABILISTIC | 0.70 |
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Targeted axillary dissection (TAD) by Blue patent | Procedure | — | UNRESOLVED |
| Targeted axillary dissection (TAD) by ICG | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Indocianine Green (ICG)
- description
- ICG tracer
- interventionNames
- Procedure: Targeted axillary dissection (TAD) by ICG
- label
- Blue patent
- description
- Blue patent tracer
- interventionNames
- Procedure: Targeted axillary dissection (TAD) by Blue patent
Primary outcomes (1)
- measure
- Detection rate of sentinel lymph node between tracers
- timeFrame
- 2 years
- description
- Compare the detection rate of sentinel lymph node between ICG and blue patent in cN+ patients after neoadjuvant treatment
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Breast cancer cN+ patients who undergo neadjuvant treatment. Exclusion Criteria: * Patients in whom there is a contraindication for the use of ICG. * Patients in whom there is evidence of progression of the disease after neoadjuvant treatment.
References
Publications (0)
Data not yet available
No reference posted for this study.